Comprehensive Evaluation of PD-1 Inhibitors Marketed in China Based on A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition)

Abstract

ObjectiveTo conduct a comprehensive evaluation of PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China, using A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition), and to provide a reference for the selection of and decision-making on clinical drugs in hospitals. MethodThe Sanzhi drug evaluation and selection system was used to evaluate the PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China, according to five characteristics: pharmaceutical characteristics, efficiency, safety, economy, and others. ResultsBased on the above evaluation criteria, the scores of all PD-1 inhibitors were above 61 points. The main difference among the five characteristics were efficiency and economy. The difference between the other characteristics was relatively small. Sintilimab injection had the highest score due to the advantages among characteristics except the other attributes. Nivolumab injection (100 mg/10 ml (10 mg/ml)) had the lowest total score due to its low effectiveness and economy scores. ConclusionPD-1 inhibitors are effective therapeutic drugs for immunotherapy in patients with advanced non-small cell lung cancer. Different PD-1 inhibitors have different advantages in clinical treatment. The comprehensive evaluation of PD-1 inhibitors for the treatment of advanced non-small cell lung cancer on the market in China through A Quick Guide for Drug Evaluation and Selection of Chinese Medical Institutions (Second Edition) can provide a basis for drug selection and scientific, reasonable, and safe drug use in medical institutions.